ORIC Pharmaceuticals, Inc.
NASDAQ Global SelectTotal Valuation
ORIC Pharmaceuticals, Inc. carries a market capitalization of 811.58M, placing it among publicly traded companies globally.
| Market Cap | 811.58M |
| Enterprise Value | N/A |
Share Statistics
ORIC Pharmaceuticals, Inc. currently has 103.49M shares outstanding.
| Shares Outstanding | 103.49M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -1.68 |
| P/TBV Ratio | 2.94 |
| P/FCF Ratio | -11.04 |
| P/OCF Ratio | -11.00 |
Financial Position
ORIC Pharmaceuticals, Inc. maintains a current ratio of 16.33, meaning it holds 16.3x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 16.33 |
| Quick Ratio | 15.86 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -39.79 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
ORIC Pharmaceuticals, Inc.'s stock has declined approximately -6.66667% over the past 52 weeks. The 50-day moving average sits at 9.64, while the 200-day moving average is 10.81.
| Beta (5Y) | N/A |
| 52-Week Price Change | -6.66667% |
| 50-Day Moving Average | 9.64 |
| 200-Day Moving Average | 10.81 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -148.72M, while operating income came in at -149.90M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -149.90M |
| Pretax Income | -135.21M |
| Net Income | -135.21M |
| EBITDA | -148.72M |
| EBIT | -149.90M |
| Earnings Per Share (EPS) | -1.40 |
Balance Sheet
Total book value stands at -728.00M, with working capital of 272.46M providing operational flexibility.
| Cash & Cash Equivalents | 281.93M |
| Total Debt | N/A |
| Net Debt | -56.40M |
| Equity (Book Value) | -728.00M |
| Book Value Per Share | -7.56 |
| Working Capital | 272.46M |
Cash Flow
ORIC Pharmaceuticals, Inc. produced -110.87M in operating cash flow over the past twelve months. After subtracting -327,000.00 in capital expenditures, free cash flow totaled -111.20M - equivalent to -1.15 per share.
| Operating Cash Flow | -110.87M |
| Capital Expenditures | -327,000.00 |
| Free Cash Flow | -111.20M |
| FCF Per Share | -1.15 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -25.12 |
| FCF Yield | -9.06 |
Scores
ORIC Pharmaceuticals, Inc. posts an Altman Z-Score of 31.80, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 31.80 |